• Revenues impacted by timing of sales to Serum Institute of India, but other sales increased 6%
• Significant technical and commercial progress across Advanced Battery Technologies and Life Sciences business units
• Secured new Life Sciences customers and increased customer evaluations globally

AnteoTech Ltd reported its Interim Financial Results for the half year ended 31 December 2025. Revenues for the period were impacted by the timing of sales to the Serum Institute of India, which has a five-year $US1.8m take or pay commercial supply agreement. However, excluding these sales, revenues from other parties increased by 6%. The company made significant progress across its Advanced Battery Technologies and Life Sciences business units during the period. In Advanced Battery Technologies, AnteoTech achieved a key technical milestone for its Ultranode™ X product, surpassing 1,000 charge/discharge cycles at 80% capacity retention. It also executed a Joint Development and Sales Agreement with Black Diamond Structures for a combined battery additive product, and completed a 10-fold manufacturing scale-up of Ultranode™ 70 for commercial evaluations. In Life Sciences, the company progressed discussions with a large global partner on a chemiluminescent immunoassay (CLIA) product incorporating its AnteoBindTM NXT technology, which demonstrated the ability to reduce antibody usage by up to six times compared to Tosyl chemistry. AnteoTech also secured new customer sales and saw a marked increase in potential customer evaluations across Europe, the US and Asia. The company continues to focus on being market-led and increasing customer engagement to drive revenue growth.